Specific inhibition of ADORA1 in the liver helps prevent body weight gain and alleviate hepatic steatosis, suggesting that ADORA1 might be a promising drug target for treating diabetes and obesity (Hong et al., 2019). Here, ADORA1 is linked to obesity disorder.